LOG IN

Members and suppliers: Join our online community

Access our full library of resources, register for events and webinars and share audits and other assessments

News

Sort By
This event was published on 31 May
Registration Open
2023 PSCI China Supplier Conference  中国供应商大会 (成都)

2023 PSCI China Supplier Conference 中国供应商大会 (成都)

Conference | 4–5 Sep 2023

2023年 PSCI 年度供应商专业发展大会将继续围绕PSCI原则,关注供应商在健康与安全环境劳工管理体系方面的能力建设。我们邀请PSCI成员、供应商及行业专家为供应商解读上述领域的最佳实践,并探讨行业面临的挑战,也使供应商有机会了解同行、合作伙伴在相关领域的优秀实践,进一步发展专业知识。

  • 会议语言 Language: 中文 Mandarin
  • 会议日期 Date: 9月4日 ,9月 5日 4th - 5th September
  • 会议时间 Time: 9:30-17:00 北京时间 9:30-17:00 Beijing time
  • 地点 Location: 成都龙之梦酒店(成都市成华区嘉陵江路8号) Chengdu Longemont Hotel
  • 报名指南 How to register: 点击下方REGISTER NOW > 用英文填写报名信息(PSCI注册用户请先行登录,系统将自动填写您的信息)> 勾选报名场次 > 点击右下角 ‘Register' 提交报名。为准确统计每天的参会人数,如您仅参加第一天/第二天的会议,请按需准确选择。

报名成功后,您的报名邮箱将收到系统自动发出的确认邮件。参会指引信息将于8月初发送至您的报名登记邮箱。您可点击如下 “Add to Calendar” 添加至日历提醒。若有任何注册相关问题,请联系秘书处 danran.chen@carnstone.com; rebecca.luo@carnstone.com.

目前多个议题的演讲嘉宾/讲师正在招募中,如您愿意作为讲师/参与互动分享,请联系PSCI秘书处Rebecca Luo (rebecca.luo@carnstone.com);Danran Chen (danran.chen@carnstone.com) 。嘉宾/讲师需求详见以下议程。

9月4日: 管理体系 Mgmt System | 用工与商业伦理 Labor & Ethics | 环保减碳 Env
4 Sep 2023 09:30–17:00 Beijing

建议参会人员:公司管理层、人力资源、环境战略部门
Recommended for: Senior management, HR, Environment departments

暂定议程 Tentative agenda:

  • Demystifying Management Systems 如何着手建立管理体系
  • Tackling Excessive Overtime & Addressing Business Ethics 加班工时与商业伦理 (讲师/互动环节嘉宾招募中) 如您有意主讲/加入该议题的讨论环节,请联系秘书处 Danran(danran.chen@carnstone.com))
  • Best Practices and Challenges in Environmental Protection 医药行业环保实践与挑战 (讲师招募中) 如您有意主讲,请联系秘书处Danran(danran.chen@carnstone.com)
  • Scope 3 Emission Management 范围三减排的最佳实践

9月5日:安全 Safety | 工业卫生 Industrial Hygiene | 环境 Environment
5 Sep 2023 09:30–17:00 Beijing

建议参会人员:EHS 管理人员、供应链经理等
Recommended for: EHS professionals, Supply chain managers

暂定议程 Tentative agenda:

  • Warehouse Safety_General Safety 仓库安全总览
  • Warehouse Safety_Process Safety 仓库安全:危险仓储与运输 (讲师招募中) 如您有意主讲,请联系秘书处 Danran(danran.chen@carnstone.com)
  • Exposure Control and Monitoring (Supplier case study) 供应商案例分享:暴露监测与分析
  • Potent Compounds_Arriving at Control Strategy 活性药物管控
  • PiE/AMR Regulatory Development in 环境中药物与抗生素法规趋势
  • Spills and Safe Containment 溢出与安全控制
Type
Conference
Date
4–5 Sep 2023
Language
Mandarin
Add To Calendar Presentation Proposal

If you have a PSCI account, please log in first so your information will be filled automatically.

All fields are required except where specified. Please enter all information in English.

Full Members

  • Abbott
  • AbbVie
  • Acino International AG
  • AstraZeneca
  • BASF Pharma
  • Baxter
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Catalent
  • Centrient Pharmaceuticals
  • Coloplast
  • Dr. Reddy's
  • Elanco Animal Health
  • GSK
  • Haleon
  • Johnson & Johnson
  • Lilly
  • Mallinckrodt
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Orion
  • Pfizer
  • Piramal
  • Roche
  • Sanofi
  • Sartorius
  • STA Pharmaceuticals
  • Takeda
  • Teva
  • UCB
  • Viatris
  • West Pharmaceutical Services Inc.

Associate Members

  • Almirall
  • Amgen
  • Aragen Life Sciences
  • Aspen Pharmacare
  • Aurobindo
  • Beckton Dickinson
  • Biogen
  • Charles River Laboratories
  • Chiesi
  • Chugai Pharmaceutical
  • Cipla
  • CSL Limited
  • Eisai Co., Limited
  • Esteve
  • Evolan Pharma AB
  • Fabbrica Italiana Sintetici S.p.a.
  • Gilead
  • Immedica Pharma
  • IOI Oleo
  • Karo Pharma
  • LEO Pharma
  • Lonza
  • Mallax Pharmaceutical
  • Merck KGaA
  • Nordic Pharma B.V.
  • Organon
  • Orifarm
  • Perrigo Company
  • Porex
  • Reckitt
  • Sai Life Sciences
  • Shionogi
  • SK Biopharmaceuticals
  • Sobi
  • Sterling Pharma Solutions
  • ten23 health
  • Tiefenbacher Group
  • Vertex
  • Vetoquinol
  • Xellia Pharmaceuticals
  • Zoetis

Please indicate which sessions you plan to attend:

4 Sep 2023

5 Sep 2023

We will not pass on these details to third parties and will use them only to contact you about this event, or other PSCI events we think you may be interested in.

Please contact us if you find you can no longer attend.

I understand that these details will be used by the PSCI to identify me and to send me communications relating to this, and future, PSCI events.

Leave this field blank if you are a human.
Registration Closes: 18 Aug 2023
If you have a user account, please log in before registering.
  • Ethics
  • Human Rights & Labor
  • Health & Safety
  • Process Safety
  • Environment
  • Management Systems
  • Data Security
  • Waste Management
  • Pharmaceuticals In The Environment
  • Anti-Microbial Resistance
  • Audit Program
This resource was published on 30 May
PSCI Position Paper on the Use of Horseshoe Crabs

PSCI Position Paper on the Use of Horseshoe Crabs

Publication

The Pharmaceutical Supply Chain Initiative (PSCI) has released a position paper on the use of Horseshoe Crabs in the pharmaceutical sector. The paper takes a progressive stance, noting the potential animal welfare and sustainability impacts of the use of Horseshoe Crab blood within the industry, and aims to encourage its member companies to minimize their use and seek out safe alternatives for their supply chains.

While this paper is not a membership requirement for the PSCI, it does outline the organization’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.

The full position paper is available to download below.

  • Ethics
  • Animal Welfare
  • Environment
This bulletin was published on 25 May
Announcing: Updated PSCI Principles now available

Announcing: Updated PSCI Principles now available

The PSCI is pleased to announce the publication of its updated Principles. The Principles underpin the work of PSCI, and form the basis of our mission. As such, we encourage all members, suppliers, and auditors to ensure they understand and are familiar with them.

The Principles have been in place, in their original form, since they were agreed by PSCI’s founding members in 2006. They were updated for the first time in December 2019. As part of our three-year periodic review, the PSCI has spent the last year in consultation with members, suppliers, partners, advisory panellists, and external stakeholders to refresh our foundational document.

Following this consultative process, all members were invited to vote to approve the new version of the Principles, which was formally adopted at the PSCI Spring Meeting on 23 May 2023.

The refreshed Principles take effect for members immediately. To ensure proper implementation, all members are now invited to start reflecting the changes in their policies, codes, processes, and practices. The first check-in will take place during the annual member calls in March 2024. All PSCI member companies are expected to have integrated the revised PSCI Principles by November 2024.

Significant changes to the Principles are:

  • ‘Governance and Management Systems’ is now the first Principle, reflecting its foundational nature and impacting the other four sections (Ethics, Human Rights, Health & Safety, and Environment)
  • Broader scope of the human rights section, now covering the rights of local communities and the commitment to conduct regular human rights risk assessments
  • New clauses on establishing a culture of responsible practices, providing remediation, setting up grievance mechanisms, protecting products and quality, upholding the right to collection bargaining, supporting the wellbeing of workers, and conserving biodiversity
  • Strengthened clauses on resource efficiency and climate change (covering suppliers' scope 3 emissions)

As ever, the Principles are made available freely and publicly to anyone with an interest in responsible supply chains for our sector. To view the Principles, visit them in our Resources library.

Any comments to the refreshed Principles, or their implementation, should be submitted to the Secretariat.

This bulletin was published on 22 May

Press Release

The Pharmaceutical Supply Chain Initiative (PSCI) Releases Position Paper on Sector’s Use of Horseshoe Crabs

  • The PSCI - representing 75 of the world’s largest pharmaceutical companies - launches progressive position paper on the use of Horseshoe Crab blood in the industry
  • Position paper addresses a range of issues to ensure sustainability and welfare of the Horseshoe Crab populations

22nd May 2023 – The Pharmaceutical Supply Chain Initiative (PSCI) just released a position paper on the use of Horseshoe Crabs in the pharmaceutical sector. The paper takes a progressive stance, noting the potential animal welfare and sustainability impacts of the use of Horseshoe Crab blood within the industry, and aims to encourage its member companies to minimize their use and seek out safe alternatives for their supply chains.

Horseshoe Crabs are an ancient group of crab species who have been around for more than 400 million years. Their blood has the remarkable property of indicating certain types of endotoxins. For this reason, it has been harvested by the medical and pharma industries to use as a test for these harmful compounds. Endotoxin testing using approved methods is a key demand of the regulators who authorize pharmaceutical development and manufacturing.

While this process does not require the death of the animal, there are still questions over possible animal welfare, biodiversity, and sustainability impacts from the collection of these materials from populations of wild crabs. Of the three affected species of Horseshoe Crabs across the US and Asia, one Asian species is listed as endangered, with concerns over the other Asian species where data is deficient.

The connection between the Horseshoe Crab species and the pharmaceutical sector highlights the importance of biodiversity for human health and acts an excellent example of interdependence between medicine and biodiversity. It also illustrates the complexity of biodiversity-related sourcing in a regulated industry.

However, it also emphasizes the need for the industry to take an active position, and so the PSCI has launched its progressive position paper on what it believes to be good practice for the use of Horseshoe Crab blood within the pharmaceutical industry.

“The PSCI is releasing this position paper to encourage our members to protect the endangered species, seek out alternatives to these materials, and to adopt an intentional approach to sourcing where it is remains necessary.

Our commitment is to work together now, to drive this transition towards a long-term sustainable position and to play our part in protecting these remarkable species.”

– A spokesperson for the PSCI

Representing 75 of the world’s largest pharmaceutical companies, the PSCI will encourage its members to commit to no further collection from endangered species, minimising the use of these materials, and sharing information to understand the animal welfare and conservation questions.

While this paper is not a membership requirement for the PSCI, it does outline the organisation’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.

Click here for the full position paper.

Please contact the PSCI at info@pscinitiative.org, or our Communications Manager, emma.wilkins@carnstone.com, if you have any questions or would like to learn more. 

About The PSCI 
Helping suppliers meet industry expectations. The PSCI was formed as a project between the 6 founding members in 2006 and was legally established in the United States as a non-profit membership organization in 2013. 

Our vision is for excellence in safety, environmental, and social outcomes for the whole of the global pharmaceutical and healthcare supply chain. Our purpose is to bring together members to define, establish, and promote responsible supply chain practices, human rights, environmental sustainability, and responsible business.

We achieve this through the PSCI Principles for Responsible Supply Chain Management. They are the blueprint for responsible practice, setting our expectations for five relevant topics: Ethics, Labor, Health & Safety, Environment, and Management Systems. 

Our strategy is based on the 6 strategic themes of: Leadership, Audit Partnering, Regional Presence, Supplier Learning, Innovation. 
www.pscinitiative.org

Follow us on:   
Twitter
LinkedIn

  • Ethics
  • Animal Welfare
  • Environment
This bulletin was published on 22 May

The use of Horseshoe Crabs in the Pharmaceutical Sector

A position paper from the PSCI

Context and background

Blood products derived from Horseshoe Crabs are used in the process of pharmaceutical development and manufacturing as endotoxin testing reagents; materials which indicate the presence of certain bacterial toxins when applied to a sample. Testing for contaminants is a crucial part of ensuring safety in drug products.

There are three affected species of Horseshoe Crabs: Limulus polyphemus found on the East Coast of the US, and the Indo-Pacific and Tri-spine Horseshoe crabs (Tachypleus gigas and Tachypleus tridentatus) found in Asia. These are used to produce Limulus Amebocyte Lysate (LAL) and Tachypleus Amebocyte Lysate (TAL) respectively, both being extracted from the animals’ blood. This does not require the death of the animal; they are typically collected, a measured amount of blood extracted, and released back into the wild.

Nonetheless, there are potentially animal welfare and sustainability impacts from the collection of these materials from populations of wild crabs, with concerns that the process may increase mortality and lead to population decline among the crabs and related species (birds and sport fish). Tachypleus tridentatus is listed as endangered[1] (with concerns over the other Asian species, where the data is deficient).

Change within the pharmaceutical industry must be carefully managed to ensure products are safe and to secure regulatory approval, however there are opportunities for progress. Good laboratory practices (automation, sample grouping, waste management) provide ways to reduce consumption. Microfluidics test technology offers accurate, reproducible tests using only a tiny fraction (as little as 5%) of the volume of LAL when compared to the traditional LAL test, dramatically reducing the demand for animal-derived product.

There are alternative technologies available in certain applications which do not require LAL or TAL at all. Recombinant Factor C (rFC) assay is an alternative to endotoxin testing using LAL/TAL. Regulators have approved rFC in some contexts; the FDA guidelines in 2012 allow for the consideration of rFC “if appropriately validated” and there is a guidance compendial test chapter in Europe. First regulatory approval using rFC for the approval of a medicine was in 2018 and this product has been approved in over 60 markets. At least seven products to date have global regulatory approvals using an alternative test reagent. Other LAL-like reagents, including a recombinant LAL, are also being introduced to the market.

The PSCI’s Position

Against this backdrop, the PSCI – representing 74 of the world’s largest pharmaceutical companies and their suppliers – is pleased to affirm the following elements of good practice, and to encourage their adoption by all members:

Protect all endangered species – no further collection of TAL. The PSCI’s members will end commercial pressure on the populations of Tachypleus gigas and Tachypleus tridentatus, by committing to no further collections from these species. PSCI members and first tier suppliers will no longer use TAL after existing supplies have been exhausted.

Minimise the requirements for naturally-derived testing materials. The PSCI recognises that members will potentially require a range of endotoxin testing techniques, and the availability of rFC, other recombinant reagents, and microfluidics offers members a route to dramatically reduce the demand for LAL. Members are encouraged to explore and adopt alternatives, setting themselves internal goals to minimize the volume of LAL used in their own operations and first tier suppliers.

Understand the animal welfare and conservation position. For the residual use of LAL, members are encouraged to take an active and intentional approach to sourcing, to understand where the material derives from and the animal welfare and biodiversity considerations that may result. Members are encouraged to co-operate and share data on traceability, populations and conservation status of Limulus polyphemus.

Governance and monitoring

This is a PSCI position paper, but it is not a formal membership requirement of PSCI; the organisation believes it to be good practice and a progressive approach to be widely adopted.

Members are encouraged to adopt positions as set out in this paper and to promote their adoption throughout the supply chain.

PSCI in turn commits to:

  • monitor and review our members’ approach on this and report it on an anonymized basis
  • engage with others to learn and develop, particularly on the US conservation position
  • prepare guidance, materials, and support to members and suppliers to implement the good practice elements of this statement
  • Ethics
  • Animal Welfare
  • Environment
This resource was published on 19 May
PSCI Annual Report 2022: Growing Connections

PSCI Annual Report 2022: Growing Connections

Report

The PSCI has published our 2022 Annual Report, summarizing a year of growing connections and clear movement towards achieving our shared vision of excellence in safety, environmental, and social outcomes across the global pharmaceutical and healthcare supply chain.

Key developments in 2022 include

  • Growth to 74 members (an increase of 40% on 2021), with 18 new Associate members
  • Developed the PSCI Maturity Models to support structured supplier learning, and in early 2023 launched an app called PSCI Maturity (available in both the Android and iOS stores)
  • 32% increase in audits available on the PSCI platform; 801 total & 196 new audits uploaded in 2022
  • Over 2,100 supplier attendees at our capability building conferences in India and China
  • Became the Official Sustainability Partner of CPHI Worldwide

Vicki Stone-Bjarup, 2022 Chair of the PSCI, says,

Sectors around the world are working to tackle the sustainability challenges of their industry. This report transparently shares the successes that PSCI members have achieved for our sector over the last year, as well as the journey left to take. There is still a long way to go, but we are so proud to be a part of the progress being made in the pharmaceutical industry. Our focus remains to support our members to build responsible supply chains.

Read about these and more in the report below.

This event was published on 7 May

Webinar: 药品对工人安全和产品安全的定量危害评估

Webinar | 18 May 2023 10:00–11:30 Beijing

本次网络研讨会将介绍 OEL 和 PDE 的概念,并讨论将风险评估方法应用于活性药物成分的非临床和临床数据,以得出科学上可靠的价值,制定用于定量监测工人暴露的遏制性能目标,并建立 分别为患者安全的可接受限度。

话题简介
药物物质和药物产品的合成、配方和整体生产涉及处理许多可能引起职业和产品安全问题的化学品。需要进行定量危害评估,以建立科学合理的工作场所暴露限度,以及一种药物作为另一种药物产品中的污染物可接受的水平。 欧洲药品管理局 (EMA) 指南中定义的每日允许暴露量 (PDE) 是一种基于健康的限值,表示在以下情况下不太可能造成不良影响的剂量(口服、静脉注射或其他规定) 一个人一生中每天都会通过这条途径接触到这一剂量或低于这一剂量。 职业接触限值 (OEL) 是工人一生中每天工作 8 小时、每周工作 40 小时的可接受限值,并用作制定接触控制措施的基础。

会议语言
本次研讨会会议语言为英语。

分享嘉宾
Allan Ader 博士是位于纽约加利福尼亚州山景城的 SafeBridge Consultants, Inc. 的联合创始人兼董事总经理,该公司是为生物技术和制药行业提供高级风险评估、安全、健康和环境支持的首要资源, 纽约、英国伯里圣埃德蒙兹和弗吉尼亚州夏洛茨维尔。

注册/登录PSCI账户后即可报名,报名将于5月15日下午17:00点截止。参会指引邮件将于5月16日发出。

Introduction
This webinar will introduce the concepts of OELs and PDEs and discuss applying risk assessment methodologies to the non-clinical and clinical data on active pharmaceutical ingredients to arrive at scientifically defensible values to develop containment performance targets for the quantitative monitoring of workers’ exposure and to establish acceptable limits for patient safety, respectively.
The synthesis, formulation, and overall production of drug substances and drug products involves the handling of numerous chemicals that have the potential to create occupational and product safety concerns.
Quantitative hazard assessment is required to establish scientifically defensible limits of exposure in the workplace as well as levels of a drug substance that are acceptable as a contaminant in another drug product. A Permitted Daily Exposure (PDE), as defined in guidance by the European Medicines Agency (EMA), is a health-based limit and represents a dose (either oral, IV, or otherwise specified) that is unlikely to cause an adverse effect if an individual is exposed, by that route, at or below this dose every day for a lifetime. An Occupational Exposure Limit (OEL) is an acceptable limit for worker exposure over an 8-hour day, 40-hour week for a worker’s lifetime and is used as a basis for establishing exposure control measures.

Language
This webinar will be held in English.

Speaker
Dr. Allan Ader is co-founder and Managing Director of SafeBridge Consultants, Inc., the premier resource for high level risk assessment, safety, health and environmental support to the biotechnology and ]pharmaceutical industry, located in Mountain View, CA, New York, NY, Bury St. Edmonds, UK and Charlottesville, VA.

To register, please sign up or log into your Link account here, registration closes at 17:00, May 15(Beijing time).

Type
Webinar
Date
18 May 2023 10:00–11:30 Beijing
Language
English
This event is in the past
This event was published on 21 March
PSCI Musi River Wastewater Workshop (In-Person Event)

PSCI Musi River Wastewater Workshop (In-Person Event)

Meeting | 26 Apr 2023 10:00–15:30 New Delhi

The Musi River flows through Hyderabad in Telangana State, Southern India. It is fed by the world-heritage Hussein Sagar Lake, also called the “heart of the world”, and used to be enjoyed by locals and tourists alike for its beauty and amenity. Yet, there have been numerous reports of polluted effluents and poor wastewater management practices affecting the lake and the Musi River watershed, impacting local communities over many years.

The PSCI aim to use our influence to engage with suppliers of PSCI members in Telangana to promote better wastewater practices and encourage positive change. Our aim is that every single supplier with a connection to a PSCI member should be contacted directly to promote the best technologies for wastewater management.

Acting on this, we are currently in the process of organising an in-person Wastewater technologies workshop in Hyderabad, India that will take place on April 26th 2023.

This workshop will be a unique opportunity to build supplier capability. The day will begin with a series of short, informative presentations followed by lunch (free of charge and provided by the hotel) and an afternoon workshop where wastewater technology companies and good-practice experts will be exhibiting their effluent treatment processes throughout the afternoon.

We have a limited capacity so please only register if you are definitely able to attend.

Type
Meeting
Date
26 Apr 2023 10:00–15:30 New Delhi
Language
English
This event is in the past
This bulletin was published on 17 February
The PSCI and Energize partner to support pharma supply chain decarbonization

The PSCI and Energize partner to support pharma supply chain decarbonization

The PSCI is delighted to welcome Energize as an official PSCI partner to support the acceleration of renewable energy adoption and enable bold climate action within the pharmaceutical sector supply chain.

In 2021, ten PSCI member companies launched a potentially game-changing collaboration to increase access to renewable energy for the pharma supply chain via the Energize Program. This first-of-its-kind industry program will enable suppliers – who may not otherwise have the internal resources or expertise available – to both learn more about and participate in the market for power purchase agreements (PPAs). The program will help pharmaceutical and healthcare suppliers to address their own operational Scope 2 greenhouse gas emissions through green power procurement, which in turn will reduce the participating companies’ Scope 3 emissions.

Renewable energy procurement can be challenging for companies of all sizes for a variety of reasons. The Energize program is designed to overcome typical market barriers such as inadequate knowledge about renewable energy transactions, load size, lack of credit, and the need for guidance throughout a complex and protracted contracting process. Participating suppliers will learn about the renewable energy market, receive guidance on PPAs, and have the opportunity to access and contract for renewable energy on their own or as part of a collaborative buyers’ cohort.

Speaking on the partnership, Rob Williams, Director - Procurement Sustainability at Astrazeneca and Co-lead of the PSCI Decarbonization Team says,

"Decarbonizing the pharma supply chain is a huge undertaking that requires partnership and collaboration. I’m delighted that the PSCI and Energize are working together to support the whole of the pharma sector supply chain through a shared value approach. By raising awareness about the world of renewable energy and providing a platform and solution for the pharma companies and their suppliers to decarbonize, we are making the transition to net zero a reality for the sector.”

John Powers, VP, Renewable Energy & Cleantech, Schneider Electric Sustainability Business says,

"We’re delighted to work together with PSCI and its member companies to accelerate the path to decarbonization through Energize – our unique, first-of-its-kind program designed for pharmaceutical and healthcare suppliers. Together, we’re enabling a more collaborative approach to Scope 3 decarbonization by helping suppliers engage renewable energy via power purchase agreements (PPAs) and meaningfully impacting the total pharma value chain.”

You can find out more about the partnership in this webinar recording presented by the PSCI and Energize teams (available to those registered with the PSCI).

About Energize
The Energize program is designed and delivered by Schneider Electric; the pharmaceutical companies promote the program collectively, and individually invite their suppliers to participate. Current corporate members include Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, Teva Pharmaceuticals, and UCB.

This event was published on 13 February
PSCI x SMI Health Systems Task Force Webinar: Supplier Targets

PSCI x SMI Health Systems Task Force Webinar: Supplier Targets

Webinar | 16 Mar 2023 13:00–14:00 London

Join us on March 16th at 1:00PM GMT (09.00EST)

In 2022, the PSCI and Sustainable Markets Initiative Health Systems Task Force Members worked together to develop a set of joint climate & sustainability targets for their suppliers. PSCI was engaged as part of the effort and will be including the standards into the existing maturity model.

The aim of this webinar is to:
• Provide an overview of the work of the Task Force and PSCI to support decarbonisation of health care supply chains
• Announce the Task Force’s joint supplier sustainability targets and discuss implications for suppliers

The SMI Health Systems Task Force was launched at the 26th United Nations Climate Change Conference (COP26) with the central aim of accelerating the delivery of net zero, patient-centric healthcare systems that improve individual, societal, and planetary health. The public-private partnership brings together CEOs and leaders from AstraZeneca, GSK, Merck, Novo Nordisk, Roche, Samsung Biologics, Sanofi, the Karolinska Institutet, National Health Service England, the Sustainable Healthcare Coalition, UNICEF, the University of Pavia, and the World Health Organization (WHO).

Task Force members aligned on a set of joint targets and engaged with suppliers and with PSCI during the process. The key dimensions of the targets were published at COP27 as part of the SMI Health Systems Task Force whitepaper on Decarbonising Supply Chains.

Speakers include:

  • Victoria Elizabeth Stone-Bjarup: Former PSCI Chair and Novo Nordisk Programme Manager for Responsible Sourcing to introduce the partnership.
  • James Choi:Executive Vice President, Chief Marketing Officer, Head of Sales Support Center at Samsung Biologics / Supplier Standards Initiative Lead for SMI Health Systems Task Force.

Date and time: March 16th - 1.00 - 2pm UK time (09:00 - 10:00am US ET)

Join link: HERE

Webinar number:
2401 685 0052

Webinar password:
KnJeqymB436 (56537962 from phones)

Join by phone
+44-203-478-5289 Call-in toll number (UK)
+1 631 267 4890 USA/Canada toll

Access code: 240 168 50052

Type
Webinar
Date
16 Mar 2023 13:00–14:00 London
Language
English
This event is in the past